For newly diagnosed BRAF mutated melanoma with brain metastases, do you prefer to start with targeted therapy or with immunotherapy?

Selection of systemic therapy, targeted therapy versus checkpoint immunotherapy, relies upon a comprehensive evaluation of patient's performance status, the number, size and location of brain metastases (BMs), neurological symptoms, and the extent of extracranial disease.

1. If the patient has poor ...